Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 23, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:Â LNTH). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LANTHEUS HOLDINGS, INC. (LNTH), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE NOVEMBER 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ON ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed information regarding the company's regulatory submissions and prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 7, 2024, to May 23, 2025, Savara's defendants failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the defendants' positive statements regarding the company's business and prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses related to Savara are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for November 7, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex- ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Semler Scientific, Inc. ("Semler Scientific, Inc." or the "Company") (NASDAQ: SMLR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Semler Scientific, Inc. investors who were adversely affected by alleged securities fraud between March 10, 2021 and April 15, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.c ...

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [2]. - As a result, the statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - Tronox Holdings plc is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 12, 2025, and July 30, 2025 [1][2] Group 1: Allegations and Financial Impact - The lawsuit claims that Tronox provided overly positive statements while concealing material adverse facts about its commercial division and forecasting processes, which ultimately led to declining sales and increased costs [2] - On July 30, 2025, Tronox reported a significant reduction in TiO2 sales for the second quarter, attributing the decline to a softer coatings season and heightened competition, which resulted in a lowered full-year revenue guidance and a 60% reduction in dividends [2] - Following the announcement, Tronox's stock price plummeted from $5.14 per share to $3.19 per share on July 31, 2025, marking a decline of approximately 38% in just one day [2] Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until November 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against C3.ai, Inc. due to alleged securities fraud affecting investors between February 26, 2025, and August 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management made overly positive statements while concealing material adverse facts about the company's growth, particularly regarding the health of its CEO and its impact on deal closures [2]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing the poor performance to "the reorganization with new leadership" and the CEO's health issues [2]. - Following the announcement, C3.ai's stock price dropped from $22.13 per share to $16.47 per share, marking a decline of approximately 25.58% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lantheus-holding ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit-subm ...

Core Viewpoint - Cytokinetics is facing a class action securities lawsuit due to alleged securities fraud related to the New Drug Application (NDA) for aficamten, which misled investors about the regulatory timeline and approval process [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by false statements regarding the NDA submission and approval timeline for aficamten between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly misrepresented the expected FDA approval timeline for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS) [2]. - The revelation during a May 6, 2025 earnings call indicated that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, leading to significant losses for investors when the truth was disclosed [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant period have until November 17, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and being recognized as one of the top securities litigation firms in the United States [4].